Key result
PLLA matrices embedded with PLGA nanoparticles containing nitric oxide donors prevented valvular calcification and inflammation in porcine aortic valve interstitial cells without cytotoxicity.
Why the study?
Does a PLLA matrix with NO-releasing nanoparticles prevent calcification and inflammation in porcine aortic valve interstitial cells?
Does a PLLA matrix with NO-releasing nanoparticles prevent calcification and inflammation in porcine aortic valve interstitial cells?
A novel PLLA matrix system loaded with NO donor-containing nanoparticles prevents valvular calcification and inflammation in vitro, offering a potential platform for reducing heart valve complications.
Poly(L-lactic acid) (PLLA) matrix systems incorporated with poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) containing nitric oxide (NO) donors (DETA NONOate) were developed for prevention of heart valve complications through sustained and controlled release of NO. PLLA matrices were prepared using the salt leaching method and the properties and drug release profiles were characterized. For assessment of the effects of PLLA systems on the pharmacological responses and cytotoxicity, various factors, such as calcium content, alkaline phosphatase (ALP) activity, cyclic guanosine monophosphate (cGMP) expression, intercellular adhesion molecule (ICAM-1) expression and cell viability of porcine aortic valve interstitial cells (PAVICs), were evaluated. PLLA matrices embedded with PLGA- NPs demonstrated its usefulness in alleviating the calcification rate of the VICs. The cGMP levels under osteoblastic conditions significantly increased, supporting that anticalcification activity of NO is mediated through NO-cGMP signaling pathway. The level of ICAM-1 expression in cells exposed to NO was lowered, suggesting that NO has an inhibitory activity against tissue inflammation. NO releases from PLLA matrix embedded with PLGA NPs prevented valvular calcification and inflammation without causing any cytotoxic activities. PLLA matrix system loaded with NPs containing NO donors could provide a new platform for sustained and controlled delivery of NO, significantly reducing valvular complications.
No takes yet. Share an insight, caveat, or question.
Acharya et al. (2012) studied Valvular complications (calcification and inflammation). Poly(L-lactic acid) (PLLA) matrix systems incorporated with PLGA nanoparticles containing nitric oxide (NO) donors was evaluated on Pharmacological responses and cytotoxicity (calcium content, ALP activity, cGMP expression, ICAM-1 expression, cell viability). PLLA matrices embedded with PLGA nanoparticles containing nitric oxide donors prevented valvular calcification and inflammation in porcine aortic valve interstitial cells without cytotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: